{{Rsnum
|rsid=806378
|Gene=CNR1
|Chromosome=6
|position=88149832
|Orientation=plus
|GMAF=0.1823
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CNR1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 56.9 | 36.9 | 6.2
| HCB | 57.8 | 37.8 | 4.4
| JPT | 68.2 | 31.8 | 0.0
| YRI | 92.1 | 7.9 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 57.8 | 37.8 | 4.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20107430
|Title=A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia
|OA=1
}}

{{PMID|21477106|OA=1
}} Association of genetic variation in cannabinoid mechanisms and gastric motor functions and satiation in overweight and obesity.

{{PMID|21803011|OA=1
}} Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

{{PMID|22288893|OA=1
}} Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

{{PMID Auto
|PMID=23277265
|Title=Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients
}}

{{PMID Auto
|PMID=23306084
|Title=Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}